Appropriate selection of the managements based on the understanding of diabetic macular edema
10.3760/cma.j.issn.2095-0160.2012.02.001
- VernacularTitle:在正确认识糖尿病性黄斑水肿的基础上合理选择其治疗方法
- Author:
Shi-bo, TANG
- Publication Type:Journal Article
- Keywords:
Ranibizumab;
Anti-angiogenesis;
Corticosteroid;
Diabetic macular edema;
Diabetic retinopathy
- From:
Chinese Journal of Experimental Ophthalmology
2012;30(2):97-100
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic macular edema (DME) is one of causes leading to visual acuity loss in the diabetic population.In recent years,great progress has been achieved in the treatment for DME.While laser photocoagulation and pars plana vitrectomy remain the standard of care,a new wave of methods,including intravitreal corticosteroid and anti-vascular endothelial growth factor (anti-VEGF) medications,is emerging and shows the preliminary safety and efficacy profile for DME by a number of clinical trials.This article introduce the definition,classification,pathogenesis and the different treatment methods for DME,so to aid ophthalmologists in evaluating the most appropriate and up-todate management options in managing DME.Particular attention is paid to summarize recent peer-reviewed literatures of ranibizumab (Lucentis).
